98%
921
2 minutes
20
The systematic use of Single Antigen Flow Beads assays and the implementation of high-resolution HLA typing for donors and kidney transplant recipients allow a precise identification of anti-HLA donor-specific antibodies. In France, the availability of detailed molecular biology HLA typing for deceased donors in the national organ allocation software enables anticipation of wet crossmatch results and estimation of the immunological risk for a recipient/donor pair. This key process, named virtual crossmatching, involves a thorough analysis of the recipient's anti-HLA sensitisation records. Its main goal is to reduce cold ischaemia time in order to extend graft survival. In this article, we present the guidelines for virtual crossmatching developed by a working group from the French-speaking Society of Histocompatibility and Immunogenetics. The guidelines address several considerations regarding HLA typing, anti-HLA antibody testing, and sensitisation event history, which are required to perform virtual crossmatching. We also propose a decision-making process, which situates prospective or retrospective wet crossmatch depending on virtual crossmatch results. The guidelines specifically emphasise the need for a strong clinical-biological agreement to standardise practices and provide a framework for omission of wet crossmatch for both non-sensitised and sensitised recipients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1111/tan.70171 | DOI Listing |
Background: Deceased donor kidney transplants often face delays, leading to prolonged cold ischemia time (CIT), yet data on post-allograft arrival delays are scarce.
Objectives: This audit aims to identify and characterize the delays contributing to CIT prolongation after allograft arrival at the implanting center.
Design: Data was collected prospectively from 14 UK centers between February and September 2022.
BMJ Case Rep
July 2025
Cardiovascular Medicine, University of Kentucky, Lexington, Kentucky, USA.
Viral infections have been associated with acute allograft rejection in solid organ transplant recipients. Influenza infection upregulates host proinflammatory cytokines, suggesting the host immune response can precipitate graft rejection. Pandemic influenza, specifically, was associated with rejection in multiple renal allograft recipients.
View Article and Find Full Text PDFHLA
July 2025
CHU de Bordeaux, Laboratoire D'immunologie et Immunogénétique, Hôpital Pellegrin, Bordeaux, France.
In organ transplantation, immunological risk assessment uses cell crossmatch (XM) results, which can be altered by several drugs. We observed two recipients awaiting kidney and liver transplantation with positive flow cytometry XM (FCXM) on T-cells in the absence of Donor Specific Antibodies (DSA). Both were treated with vedolizumab (VDZ) for an inflammatory bowel disease (IBD).
View Article and Find Full Text PDFAm J Transplant
June 2025
Department of Pathology and Laboratory Medicine, Emory University School of Medicine, Atlanta, Georgia, USA.
Donor-specific anti-human leukocyte antigen (HLA) antibodies are a significant barrier to solid organ transplant and can lead to poor outcomes in the posttransplant setting. Physical crossmatch (PXM), including complement-dependent cytotoxicity crossmatch and flow cytometric crossmatch, has substantially reduced the incidence of hyperacute rejection and, for years, has been the gold standard for compatibility assessment before transplant. However, the advent of solid-phase anti-HLA antibody testing and molecular HLA typing has allowed the introduction and rise of virtual crossmatch (VXM).
View Article and Find Full Text PDFHum Immunol
July 2025
UCLA Immunogenetics Center, Department of Pathology & Laboratory Medicine, David Geffen School of Medicine at Los Angeles, CA, USA.
A 36-year-old, highly sensitized (cPRA 99.99 %) male listed for his third kidney transplant for more than 12 years received a deceased donor offer. The virtual crossmatch (VXM) indicated that the patient had two weak donor-specific antibodies (DSA) to DR10 and DP17 against potential Donor 1, which would correlate with a negative T/B physical crossmatch (PXM).
View Article and Find Full Text PDF